Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Abstract

The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.).

Keywords

MedicineReactogenicitymyalgiaAdverse effectRegimenCohortPlaceboInternal medicineInterim analysisViral loadImmunologyClinical trialVirusImmunogenicityPathology

Affiliated Institutions

Related Publications

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich , Sumathi Sivapalasingam , Thomas Norton +30 more

In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a hig...

2020 New England Journal of Medicine 1763 citations

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Jerald Sadoff , Glenda Gray , An Vandebosch +27 more

A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe-critical disease, including hospitaliz...

2021 New England Journal of Medicine 2522 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a v...

2020 The Lancet 2590 citations

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov , Inna V. Dolzhikova , Dmitry V. Shcheblyakov +28 more

A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in pa...

2021 The Lancet 1799 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Publication Info

Year: 2021
Type: article
Volume: 384
Issue: 19
Pages: 1824-1835
Citations: 1153
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1153

OpenAlex

Cite This

APA Style

                            
                                
                                    Jerald Sadoff, 
                                
                                    Mathieu Le Gars, 
                                
                                    Georgi Shukarev
                                
                                et al.
                            
                            (2021). 
                            Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. 
                            New England Journal of Medicine
                            , 384
                            (19)
                            , 1824-1835.
                            https://doi.org/10.1056/nejmoa2034201
                        

Identifiers

DOI: 10.1056/nejmoa2034201